Updated Prognostic Factors in Localized NSCLC

Garinet, Simon; Wang, Pascal; Lupo, Audrey; Fournel, Ludovic; Wislez, Marie; Blons, Hélène

doi:10.3390/cancers14061400

Cited by 52 publications

(43 citation statements)

References 128 publications

(153 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BMI, a surrogate of nutritional status, has been regarded as a prognostic factor in both localized 8 and advanced lung cancer 17 . In these reports, overweight is associated with better survival.…”

Section: Discussionmentioning

confidence: 99%

“…Prognostic factors that affect NSCLC are extensively studied. Various clinical factors have been identified as prognostic in different contexts, for example, age, sex and performance status, etc 8,9 . The process of metastasis is thought as nonrandom and therefore the metastatic pattern may also harbor a prognostic implication 10 .…”

Section: Introductionmentioning

confidence: 99%

“…Various clinical factors have been identified as prognostic in different contexts, for example, age, sex and performance status, etc. 8,9 The process of metastasis is thought as nonrandom and therefore the metastatic pattern may also harbor a prognostic implication. 10 However, fewer clinical studies investigate the prognostic factors focusing on LUSC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Real‐world treatment pattern and prognostic factors of stage IV lung squamous cell carcinoma patients

Hsu

Tsai

et al. 2022

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Lung squamous cell carcinoma (LUSC) represents a minor proportion of nonsmall cell lung cancer (NSCLC) harboring a poor prognosis. Herein, retrospective medical record research was performed to investigate real‐world treatment patterns and identify the prognostic factors among LUSC patients. A total of 173 patients with a median age of 68 years were enrolled for analysis. Males were predominant (n = 143, 83%) and current or ex‐smokers contributed to 78% of the entire cohort. Pleura and lung were the most common metastatic sites, whereas brain metastasis was only 7%. After diagnosis, however, only 107 patients (62%) had received first‐line chemotherapy. In the chemotherapy cohort, median progression‐free survival (PFS) and overall survival (OS) were 3.9 and 11.1 months, respectively. After multivariable analysis, bone metastasis and the use of first‐line single‐agent chemotherapy independently predicted shorter PFS. For baseline characteristics, male sex, metastasis to lung, pleura, liver, and bone independently predicted worse OS. Regarding the treatment pattern, patients who had undergone standard first‐line doublet therapy and employed targeted therapies after disease progression linked to longer OS. In the real world, even those who underwent chemotherapy still had poor outcome. The findings may help clinicians to orchestrate the treatment strategies for LUSC patients and provide further direction of large‐scale studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real‐world treatment pattern and prognostic factors of stage IV lung squamous cell carcinoma patients

Hsu

Tsai

et al. 2022

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…Currently, TNM staging is the main basis for determining lung cancer prognosis. However, its effectiveness is limited by the fact that clinical outcomes for different patients at the same TNM stage can vary significantly [17]. Disease progression is influenced by immune cell infiltrations in the TME.…”

Section: Discussionmentioning

confidence: 99%

Identification of Prognostic Genes and Immune Landscape Signatures Based on Tumor Microenvironment in Lung Adenocarcinoma

et al. 2022

View full text Add to dashboard Cite

Background. Lung adenocarcinoma is the most common lung cancer subtype and accounts for the highest proportion of cancer-related deaths. The tumor microenvironment influences prognostic outcomes in lung adenocarcinoma (LUAD). Materials and Methods. We used the ESTIMATE algorithm (Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) to investigate the role of microenvironment-related genes and stromal cells in lung adenocarcinoma prognosis. This analysis was done on lung adenocarcinoma cases from The Cancer Genome Atlas (TCGA). The cases were divided into high and low groups on the basis of immune and stromal scores, respectively. Results. There were close correlations between immune scores with prognosis and disease stage. There were 367 differentially expressed genes. Combining the Gene Expression Omnibus (GEO) database, we found 14 prognosis-related genes. Results. Based on the enrichment levels of the immune cell types, we clustered LUAD into Immunity_H and Immunity_L subtypes. Most of these genes were upregulated in Immunity_H subtype. Finally, using the Human Protein Atlas (HPA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) databases, most of the proteins corresponding to prognostic genes were verified to be differentially expressed between the tumor and normal groups. Conclusions. The key genes identified in this study are involved in molecular mechanisms of LUAD.

show abstract

“…Non-Small Cell Lung Carcinoma (NSCLC). NSCLC is a leading cause of cancer mortality [ 171 ]. As described for ovarian cancer, miR-139-3P downregulation contributes to HuR overexpression in lung cancer cells [ 172 ].…”

Section: Mirnas-regulating Hur and Ttp Family Membersmentioning

confidence: 99%

MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes

Sobolewski

Dubuquoy

Legrand

2022

Cancers

View full text Add to dashboard Cite

MicroRNAs represent the most characterized post-transcriptional regulators of gene expression. Their altered expression importantly contributes to the development of a wide range of metabolic and inflammatory diseases but also cancers. Accordingly, a myriad of studies has suggested novel therapeutic approaches aiming at inhibiting or restoring the expression of miRNAs in human diseases. However, the influence of other trans-acting factors, such as long-noncoding RNAs or RNA-Binding-Proteins, which compete, interfere, or cooperate with miRNAs-dependent functions, indicate that this regulatory mechanism is much more complex than initially thought, thus questioning the current models considering individuals regulators. In this review, we discuss the interplay existing between miRNAs and the AU-Rich Element Binding Proteins (AUBPs), HuR and tristetraprolin family members (TTP, BRF1 and BRF2), which importantly control the fate of mRNA and whose alterations have also been associated with the development of a wide range of chronic disorders and cancers. Deciphering the interplay between these proteins and miRNAs represents an important challenge to fully characterize the post-transcriptional regulation of pro-tumorigenic processes and design new and efficient therapeutic approaches.

show abstract

Updated Prognostic Factors in Localized NSCLC

Cited by 52 publications

References 128 publications

Real‐world treatment pattern and prognostic factors of stage IV lung squamous cell carcinoma patients

Real‐world treatment pattern and prognostic factors of stage IV lung squamous cell carcinoma patients

Identification of Prognostic Genes and Immune Landscape Signatures Based on Tumor Microenvironment in Lung Adenocarcinoma

MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes

Contact Info

Product

Resources

About